Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality

Sohag University40 enrolled

Overview

Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hematological Malignancies

Interventions

Flowcytometry on bone marrow aspirationDIAGNOSTIC_TEST

Flowcytometry on bone marrow aspiration

Eligibility

Sex: ALLMin age: 1 YearMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Newly diagnosed cases of hematological malignancis. Exclusion Criteria: * Known cases of hematological malignancies and on treatment.

Primary Outcomes

Level of CD200 diagnostic marker assessed by flow cytometry

Prognostic value of CD200 in hematological malignancies

Time frame: one year

Central Contacts

Reem ya Hashim, resident

CONTACT

01285481488 reem011091@med.sohag.edu.eg

sherine Ph aziz, resident

CONTACT

01227848855